Trial With Azacitidine in Newly Diagnosed Acute Myelogenous Leukemia (AML) Veterans Administration (VA) Elderly Patients Not Eligible for Standard Induction Therapy

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.

Verified August 2008 by Kansas City Veteran Affairs Medical Center.
Recruitment status was: Recruiting

Sponsor:

Information provided by:

Kansas City Veteran Affairs Medical Center

ClinicalTrials.gov Identifier:

NCT00728520

First received: July 31, 2008

Last updated: August 5, 2008

Last verified: August 2008

History of Changes

Purpose

The drug that will be used in this study is called Azacitidine. Azacitidine belongs to a group of drugs which may restore normal control in cancer cells by affecting the genes and proteins in the body. Azacitidine is approved by the FDA for the treatment of Myelodysplastic Syndrome (MDS), a pre-leukemic bone marrow disease. The purpose of this study is to find out what effect the drug Azacitidine has on Acute Myeloid Leukemia (AML) in elderly patients.

Condition	Intervention	Phase
Acute Myeloid Leukemia Elderly	Drug: Azacitidine	Phase 2


Study Type:	Interventional
Study Design:	Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment
Official Title:	A Phase II Trial With Azacitidine Single Agent in Newly Diagnosed Acute Myelogenous Leukemia (AML) Veterans Administration (VA) Elderly Patients Who Are Ineligible for Standard Induction Therapy: A Department of Veterans Affairs Multi-Site Study

Resource links provided by NLM:

Genetics Home Reference related topics: core binding factor acute myeloid leukemia cytogenetically normal acute myeloid leukemia familial acute myeloid leukemia with mutated CEBPA

MedlinePlus related topics: Acute Myeloid Leukemia Leukemia

Drug Information available for: Azacitidine

Genetic and Rare Diseases Information Center resources: Myeloid Leukemia Acute Myeloid Leukemia Acute Non Lymphoblastic Leukemia

U.S. FDA Resources

Further study details as provided by Kansas City Veteran Affairs Medical Center:

Primary Outcome Measures:

overall response rates, duration of response, toxicities [ Time Frame: Starting 4 weeks after treatment, during the entire study duration, and upon study completion ]

Secondary Outcome Measures:

leukemia free survival, overall survival, quality of life, assess biomarkers and predictive markers for Azacitidine responsiveness in elderly AML patients [ Time Frame: During the entire duration of the study and after study completion ]


Estimated Enrollment:	40
Study Start Date:	July 2008
Estimated Study Completion Date:	June 2012
Estimated Primary Completion Date:	June 2010 (Final data collection date for primary outcome measure)

Intervention Details:

Azacitidine 75 mg/m2 daily IV or subcutaneously (SQ) for 5 days, every 4 weeks for a minimum of 4 cycles.

Other Name: Vidaza

Detailed Description:

Prior to starting treatment individuals being considered for this study will be evaluated to determine if they are eligible to participate in the study. There are certain prestudy test that are required: physical exam, blood tests, ECG, chest x-ray, bone marrow aspirate and biopsy to confirm the diagnosis of AML.

Treatment regimen consists of Azacitidine IV/SQ on days 1-5 every 28 days. If the Azacitidine is given IV it will be given over 15-40 minutes. The treatment will be given for a minimum of 4 treatment cycles. Blood samples will be taken every week to monitor for side effects of the Azacitidine. A bone marrow aspirate will be done every 3-4 months to determine the response to the study drug or until the disease progresses. There is also a quality of life questionnaire that will be completed at the beginning of the study and every 4 weeks while on the study.

Eligibility


Ages Eligible for Study:	60 Years and older (Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Diagnosis of AML
Elderly patients with denovo AML or secondary AML evolving from MDS in patient >/= 60 who decline chemotherapy or those who are not currently candidates for induction chemotherapy
Stable WBC <10 x 109 and not requiring hydroxyurea, chemotherapy or leukapheresis for >4 weeks
No corticosteroids, hydroxyurea, low-dose cytarabine, interferon, ir retinoids within 1 month
No prior decitabine
No valproic acid or other histone deacetylase inhibitor for at least 2 weeks
No G-CSF, or GM-CSF or Erythropoetin within 1 month of study entry
No investigational agents within 28 days
ECOG performance status </= 2 or KPS >/= 60%
Life expectancy > 2 months
Normal organ function = Total bilirubin </= 1.5 x ULN, AST/ALT </= 2.5 x ULN
Creatinine within normal limits or creatinine clearance >/= 60ml/min
Signed informed consent

Exclusion Criteria:

Patients with t(15;17) or M3-AML
Patients who have had chemotherapy or radiotherapy within 4 weeks prior to study entry, or who have not recovered from adverse effects of agents administered earlier
Patients with CNS involvement of AML
History of allergic reactions attributed to Azacitidine or compounds of similar chemical used in this study
Pregnancy
Other serious medical or psychiatric illness which would limit survival to < 3 months or prevent the granting of informed consent or lead to situations that would limit compliance with study requirements
Known positive serology for HIV, HIV positive patients with anti-retroviral therapy are ineligible
Active systemic bacterial, fungal or viral infection
Patients with severe complications of the leukemia including but not limited to active infection, uncontrolled infection, pneumonia, hypoxia, and shock
Patients with advanced hepatic tumors
Patients with poor history of medical compliance
Patients with known platelet refractoriness

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00728520

Contacts


Contact: Sarah Spencer, RN, BSN	816-861-4700 ext 57665	sarah.spencer@va.gov
Contact: Suman Kambhampati, MD	816-861-4700	suman.kambhampati@va.gov

Locations


United States, Missouri
Kansas City Veterans Affairs Medical Center	Recruiting
Kansas City, Missouri, United States, 64218
Contact: Sarah E Spencer, RN, BSN 816-861-4700 ext 57665 sarah.spencer@va.gov
Contact: Suman Kambhampati, MD 816-861-4700 ext 57075 suman.kambhampati@va.gov
Principal Investigator: Suman Kambhampati, MD
Sub-Investigator: Peter J. Van Veldhuizen, MD
Sub-Investigator: Chao H. Huang, MD
Sub-Investigator: Chester Stone, MD

Sponsors and Collaborators

Kansas City Veteran Affairs Medical Center

Investigators


Principal Investigator:	Amit Verma, MD	Albert Einstein College of Medicine, Inc.

More Information


Responsible Party:	Suman Kambhampati, MD, Kansas City Veterans Affairs Medical Center
ClinicalTrials.gov Identifier:	NCT00728520 History of Changes
Other Study ID Numbers:	SK0010
Study First Received:	July 31, 2008
Last Updated:	August 5, 2008

Keywords provided by Kansas City Veteran Affairs Medical Center:


Leukemia Azacitidine Untreated Elderly

Additional relevant MeSH terms:


Leukemia Leukemia, Myeloid, Acute Leukemia, Myeloid Neoplasms by Histologic Type Neoplasms Azacitidine	Antimetabolites, Antineoplastic Antimetabolites Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Enzyme Inhibitors

ClinicalTrials.gov processed this record on July 21, 2017

To Top